Literature DB >> 29952931

Grading Severity and Activity in Thyroid Eye Disease.

Peter J Dolman1.   

Abstract

PURPOSE: Thyroid eye disease (TED) is an autoimmune disorder causing inflammation, expansion, and fibrosis of orbital fat, muscle, and lacrimal gland. This article reviews the different methods of grading severity and activity of TED and focuses on the VISA Classification for disease evaluation and planning management.
METHODS: Accurate evaluation of the clinical features of TED is essential for early diagnosis, identification of high-risk disease, planning medical and surgical intervention, and assessing response to therapy. Evaluation of the activity and severity of TED is based on a number of clinical features: appearance and exposure, periorbital tissue inflammation and congestion, restricted ocular motility and strabismus, and dysthyroid optic neuropathy. The authors review these clinical features in relation to disease activity and severity.
RESULTS: Several classification systems have been devised to grade severity of these clinical manifestations. These include the NO SPECS Classification, the European Group on Graves Orbitopathy severity scale, the Clinical Activity Score of Mourits, and the VISA Classification as outlined here. The authors compare and contrast these evaluation schemes.
CONCLUSIONS: An accurate clinical assessment of TED, including grading of disease severity and activity, is necessary for early diagnosis, recognition of those cases likely to develop more serious complications, and appropriate management planning. The VISA Classification grades both disease severity and activity using subjective and objective inputs. It organizes the clinical features of TED into 4 discrete groupings: V (vision, dysthyroid optic neuropathy); I (inflammation, congestion); S (strabismus, motility restriction); A (appearance, exposure). The layout follows the usual sequence of the eye examination and facilitates comparison of measurements between visits and data collation for research.

Entities:  

Mesh:

Year:  2018        PMID: 29952931     DOI: 10.1097/IOP.0000000000001150

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  8 in total

1.  Non-EPI-DWI for Detection, Disease Monitoring, and Clinical Decision-Making in Thyroid Eye Disease.

Authors:  C Feeney; R K Lingam; V Lee; F Rahman; S Nagendran
Journal:  AJNR Am J Neuroradiol       Date:  2020-08       Impact factor: 3.825

2.  Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy.

Authors:  Jonathan C P Roos; Vignesh Paulpandian; Rachna Murthy
Journal:  Eye (Lond)       Date:  2018-11-06       Impact factor: 3.775

3.  Detection of active and inactive phases of thyroid-associated ophthalmopathy using deep convolutional neural network.

Authors:  Chenyi Lin; Xuefei Song; Huifang Zhou; Xianqun Fan; Lunhao Li; Yinwei Li; Mengda Jiang; Rou Sun
Journal:  BMC Ophthalmol       Date:  2021-01-14       Impact factor: 2.209

Review 4.  The roles of sex and gender in women's eye health disparities in the United States.

Authors:  Irene O Aninye; Kathleen Digre; M Elizabeth Hartnett; Kira Baldonado; Erin M Shriver; Laura M Periman; Julie Grutzmacher; Janine A Clayton
Journal:  Biol Sex Differ       Date:  2021-10-20       Impact factor: 8.811

5.  Diffusion Tensor Imaging Technology to Quantitatively Assess Abnormal Changes in Patients With Thyroid-Associated Ophthalmopathy.

Authors:  Li Rui; Li Jing; Wang Zhenchang
Journal:  Front Hum Neurosci       Date:  2022-02-04       Impact factor: 3.169

6.  Novel observational study protocol to develop a prediction model that identifies patients with Graves' ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy.

Authors:  Yi Wang; Hui Wang; Lunhao Li; Yinwei Li; Jing Sun; Xuefei Song; Huifang Zhou
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

7.  Peripapillary structural and microvascular alterations in early dysthyroid optic neuropathy.

Authors:  Yufei Wu; Qiaoli Yang; Liujun Ding; Yunhai Tu; Xiaoyu Deng; Yan Yang; Meixiao Shen; Qinkang Lu; Fan Lu; Qi Chen
Journal:  Eye Vis (Lond)       Date:  2022-08-09

8.  Current insights of applying MRI in Graves' ophthalmopathy.

Authors:  Cheng Song; Yaosheng Luo; Genfeng Yu; Haixiong Chen; Jie Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.